浏览全部资源
扫码关注微信
左乙拉西坦治疗药物监测的研究进展
Research progress in therapy drug monitoring of levetiracetam
- 中国药房 2024年35卷第2期 页码：251-256
- 作者机构：
1.赣南医学院第一附属医院药学部，江西 赣州 341001
2.赣州市儿童白血病肿瘤免疫治疗药物研发重点实验室，江西 赣州 341000
- 作者简介：
讲师。研究方向：中药药效物质基础与先导化合物筛选、治疗药物监测。E-mail：gaochang1989.ok@163.com
主任药师。研究方向：医院药学。E-mail：weiguilin@sina.com
- 基金信息：江西省卫生健康委科技计划项目(202130626);赣州市指导性科技计划项目(GZ2021ZSF040);赣州市卫生健康委员会市级科研计划项目(2020-2-89);赣南医学院第一附属医院博士启动项目(QD074)
DOI：10.6039/j.issn.1001-0408.2024.02.23
中图分类号： R971+.6;R969纸质出版日期：2024-01-30，
收稿日期：2023-07-20，
修回日期：2023-12-20，
扫 描 看 全 文
高畅,倪斌,陈芳辉等.左乙拉西坦治疗药物监测的研究进展 Δ[J].中国药房,2024,35(02):251-256.
GAO Chang,NI Bin,CHEN Fanghui,et al.Research progress in therapy drug monitoring of levetiracetam[J].ZHONGGUO YAOFANG,2024,35(02):251-256.
高畅,倪斌,陈芳辉等.左乙拉西坦治疗药物监测的研究进展 Δ[J].中国药房,2024,35(02):251-256. DOI： 10.6039/j.issn.1001-0408.2024.02.23.
GAO Chang,NI Bin,CHEN Fanghui,et al.Research progress in therapy drug monitoring of levetiracetam[J].ZHONGGUO YAOFANG,2024,35(02):251-256. DOI： 10.6039/j.issn.1001-0408.2024.02.23.
摘要
左乙拉西坦（LEV）是第二代广谱抗癫痫药物，具有起效快、半衰期短、疗效确切、耐受性好、药物相互作用少等优点。为提高LEV的临床效果，减少不良反应的发生，应对儿童、妊娠期妇女、老年人、肾功能不全等特殊人群予以治疗药物监测（TDM）。临床上LEV监测样本常选择血浆或血清，监测方法多选择免疫分析法或色谱分析法。LEV的有效浓度范围目前尚无统一意见，血药浓度与不良反应的相关性也不明确。影响LEV血药浓度的因素主要有年龄、妊娠及患者用药依从性等。如何解读TDM结果并根据结果调整给药剂量是今后工作的重点。
Abstract
Levetiracetam （LEV） is the second generation of broad-spectrum anti-epileptic drug. LEV has the advantages of rapid absorption， short half-life， precise efficacy， good tolerance and few drug interactions. In order to improve the clinical efficacy of LEV， and reduce the occurrence of adverse reactions， children， pregnant women， the elderly， and patients with renal insufficiency should receive therapeutic drug monitoring （TDM）. Clinically， the samples are usually plasma or serum， and the TDM methods are mostly immunoassay or chromatography. There is currently no consensus on the effective concentration range of LEV， and the correlation between plasma concentration and adverse reactions is also unclear. The main factors affecting LEV plasma concentration include age， pregnancy， and patient compliance. How to interpret TDM results and adjust dosage based on the results will be the focus of future work.
关键词
左乙拉西坦治疗药物监测合理用药血药浓度
Keywords
therapeutic drug monitoringrational drug useplasma concentration
references
ALRABIAH H. Levetiracetam[J]. Profiles Drug Subst Excip Relat Methodol，2019，44：167-204.
MANREZA M L G，PAN T A，CARBONE E Q，et al. Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy[J]. Arq Neuropsiquiatr，2021，79（4）：290-298.
LYSENG-WILLIAMSON K A. Levetiracetam：a review of its use in epilepsy[J]. Drugs，2011，71（4）：489-514.
PATSALOS P N. Clinical pharmacokinetics of levetiracetam[J]. Clin Pharmacokinet，2004，43（11）：707-724.
SHAH N M，HAWWA A F，MILLERSHIP J S，et al. A simple bioanalytical method for the quantification of antiepileptic drugs in dried blood spots[J]. J Chromatogr B Analyt Technol Biomed Life Sci，2013，923/924：65-73.
MIN K L，RYU J Y，CHANG M J. Development and clinical applications of the dried blood spot method for therapeutic drug monitoring of anti-epileptic drugs[J]. Basic Clin Pharmacol Toxicol，2019，125（3）：215-236.
PATSALOS P N，GHATTAURA S，RATNARAJ N，et al. In situ metabolism of levetiracetam in blood of patients with epilepsy[J]. Epilepsia，2006，47（11）：1818-1821.
BIANCHI V，ARFINI C，VIDALI M. Therapeutic drug monitoring of levetiracetam：comparison of a novel immunoassay with an HPLC method[J]. Ther Drug Monit，2014，36（5）：681-685.
TAN J，PAQUETTE V，LEVINE M，et al. Levetiracetam clinical pharmacokinetic monitoring in pediatric patients with epilepsy[J]. Clin Pharmacokinet，2017，56（11）：1267-1285.
CONTIN M，MOHAMED S，ALBANI F，et al. Simple and validated HPLC-UV analysis of levetiracetam in deproteinized plasma of patients with epilepsy[J]. J Chromatogr B Analyt Technol Biomed Life Sci，2008，873（1）：129-132.
ENGELBRECHT L，GROBLER C J，RHEEDERS M. A simple and cost-effective HPLC-UV method for the detection of levetiracetam in plasma/serum of patients with epilepsy[J]. Biomed Chromatogr，2017，31（10）：10.1002/bmc.3969.
IBRAHIM F A，EL-YAZBI A F，BARARY M A，et al. Sensitive inexpensive HPLC determination of four antiepileptic drugs in human plasma：application to PK studies[J]. Bioanalysis，2016，8（21）：2219-2234.
GUO T D，OSWALD L M，MENDU D R，et al. Determination of levetiracetam in human plasma/serum/saliva by liquid chromatography-electrospray tandem mass spectrometry[J]. Clin Chim Acta，2007，375（1/2）：115-118.
YEAP L L，LO Y L. Rapid and simultaneous quantification of levetiracetam and its carboxylic metabolite in human plasma by liquid chromatography-tandem mass spectrometry[J]. PLoS One，2014，9（11）：e111544.
JUENKE J M，BROWN P I，JOHNSON-DAVIS K L，et al. Simultaneous quantification of levetiracetam and gabapentin in plasma by ultra-pressure liquid chromatography coupled with tandem mass spectrometry detection[J]. Ther Drug Monit，2011，33（2）：209-213.
BLONK M I，VAN DER NAGEL B C，SMIT L S，et al. Quantification of levetiracetam in plasma of neonates by ultra performance liquid chromatography-tandem mass spectrometry[J]. J Chromatogr B Analyt Technol Biomed Life Sci，2010，878（7/8）：675-681.
QI Y J，LIU G X. A UPLC-MS/MS method for simulta-neous determination of nine antiepileptic drugs in human plasma and its application in TDM[J]. Biomed Chromatogr，2021，35（7）：e5090.
GREINER-SOSANKO E，GIANNOUTSOS S，LOWER D R，et al. Drug monitoring：simultaneous analysis of lamotrigine，oxcarbazepine，10-hydroxycarbazepine，and zonisamide by HPLC-UV and a rapid GC method using a nitrogen-phosphorus detector for levetiracetam[J]. J Chromatogr Sci，2007，45（9）：616-622.
NIKOLAOU P，PAPOUTSIS I，DONA A，et al. Development and validation of a GC/MS method for the simulta-neous determination of levetiracetam and lamotrigine in whole blood[J]. J Pharm Biomed Anal，2015，102：25-32.
ANTONILLI L，BRUSADIN V，FILIPPONI F，et al. Development and validation of an analytical method based on high performance thin layer chromatography for the simultaneous determination of lamotrigine，zonisamide and levetiracetam in human plasma[J]. J Pharm Biomed Anal，2011，56（4）：763-770.
EL-YAZBI A F，WAGIH M M，IBRAHIM F，et al. Spectrofluorimetric determination of topiramate and levetiracetam as single components in tablet formulations and in human plasma and simultaneous fourth derivative synchronous fluorescence determination of their co-adminstered mixture in human plasma[J]. J Fluoresc，2016，26（4）：1225-1238.
PATSALOS P N，BERRY D J，BOURGEOIS B F，et al. Antiepileptic drugs：best practice guidelines for therapeutic drug monitoring：a position paper by the subcommission on therapeutic drug monitoring，ILAE Commission on Therapeutic Strategies[J]. Epilepsia，2008，49（7）：1239-1276.
李琳，黄桦，吴迪，等. 左乙拉西坦血药浓度影响因素探讨及参考区间的初步建立[J]. 中国临床药理学杂志，2018，34（6）：643-645.
LI L，HUANG H，WU D，et al. Reference range of levetiracetam plasma concentration and its influencing factors in our hospital[J]. Chin J Clin Pharmacol，2018，34（6）：643-645.
LANCELIN F，FRANCHON E，KRAOUL L，et al. Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection：preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy[J]. Ther Drug Monit，2007，29（5）：576-583.
STEPANOVA D，BERAN R G. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications（AEMs）[J]. Seizure，2014，23（5）：371-376.
IWASAKI T，TOKI T，NONODA Y，et al. The efficacy of levetiracetam for focal seizures and its blood levels in children[J]. Brain Dev，2015，37（8）：773-779.
SHEINBERG R，HEYMAN E，DAGAN Z，et al. Correlation between efficacy of levetiracetam and serum levels among children with refractory epilepsy[J]. Pediatr Neurol，2015，52（6）：624-628.
ALDAZ A，FERRIOLS R，AUMENTE D，et al. Pharmacokinetic monitoring of antiepileptic drugs[J]. Farm Hosp，2011，35（6）：326-339.
ITALIANO D，PERUCCA E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age：an update[J]. Clin Pharmacokinet，2013，52（8）：627-645.
JARVIE D，MAHMOUD S H. Therapeutic drug monito-ring of levetiracetam in select populations[J]. J Pharm Pharm Sci，2018，21（1s）：149s-176s.
LÓPEZ-FRAILE I P，CID A O，JUSTE A O，et al. Levetiracetam plasma level monitoring during pregnancy，deli-very，and postpartum：clinical and outcome implications[J]. Epilepsy Behav，2009，15（3）：372-375.
TOMSON T，PALM R，KÄLLÉN K，et al. Pharmacokine-tics of levetiracetam during pregnancy，delivery，in the neonatal period，and lactation[J]. Epilepsia，2007，48（6）：1111-1116.
WESTIN A A，REIMERS A，HELDE G，et al. Serum concentration/dose ratio of levetiracetam before，during and after pregnancy[J]. Seizure，2008，17（2）：192-198.
LONGO B，FORINASH A B，MURPHY J A. Levetiracetam use in pregnancy[J]. Ann Pharmacother，2009，43（10）：1692-1695.
VOINESCU P E，PENNELL P B. Management of epilepsy during pregnancy[J]. Expert Rev Neurother，2015，15（10）：1171-1187.
LI Y，WANG M L，GUO Y，et al. Population pharmacokinetics and dosing regimen optimization of levetiracetam in epilepsy during pregnancy[J]. Br J Clin Pharmacol，2023，89（3）：1152-1161.
HIRSCH L J，ARIF H，BUCHSBAUM R，et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability[J]. Epilepsia，2007，48（7）：1351-1359.
FRENCH J. Use of levetiracetam in special populations[J]. Epilepsia，2001，42（Suppl 4）：40-43.
YAMAMOTO J，TOUBLANC N，KUMAGAI Y，et al. Levetiracetam pharmacokinetics in Japanese subjects with renal impairment[J]. Clin Drug Investig，2014，34（11）：819-828.
MAHMOUD S H. Antiepileptic drug removal by continuous renal replacement therapy：a review of the literature[J]. Clin Drug Investig，2017，37（1）：7-23.
MAY T W，RAMBECK B，JÜRGENS U. Serum concentrations of levetiracetam in epileptic patients：the in-fluence of dose and co-medication[J]. Ther Drug Monit，2003，25（6）：690-699.
MINK S，MUROI C，SEULE M，et al. Levetiracetam compared to valproic acid：plasma concentration levels，adverse effects and interactions in aneurysmal subarachnoid hemorrhage[J]. Clin Neurol Neurosurg，2011，113（8）：644-648.
CRAWFORD P. Interactions between antiepileptic drugs and hormonal contraception[J]. CNS Drugs，2002，16（4）：263-272.
TOUBLANC N，DU X L，LIU Y，et al. Pharmacokinetics，safety and bioequivalence of levetiracetam intravenous infusion and oral tablets in healthy Chinese subjects[J]. Clin Drug Investig，2015，35（8）：495-503.
WANG M，WANG M M，ZHANG Q Y，et al. Pharmacokinetics and safety of levetiracetam extended-release tablets and relative bioavailability compared with immediate-release tablets in healthy Chinese subjects[J]. Eur J Drug Metab Pharmacokinet，2018，43（4）：405-413.
廖淑芳. 癫痫伴发精神障碍患者服药依从性及其影响因素分析[J]. 中国当代医药，2022，29（23）：50-52，56.
LIAO S F. Analysis of medication compliance and its influencing factors of patients with epilepsy and mental dis-order[J]. China Mod Med，2022，29（23）：50-52，56.
周艳，吴青，余春飞，等. 癫痫患儿用药依从性现状及影响因素调查分析[J]. 儿科药学杂志，2022，28（7）：21-26.
ZHOU Y，WU Q，YU C F，et al. Investigation and analysis of medication adherence and influencing factors in children with epilepsy[J]. J Pediatr Pharm，2022，28（7）：21-26.
0
浏览量
4
下载量
0
CSCD
- 网络PDF下载
- WORD下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 地址：重庆市渝中区大坪正街129号四环大厦8层 400042
- 技术支持由北京北大方正电子有限公司提供 渝ICP备15012710号
公网安备50010302001817 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies